Merriman Curhan Ford Initiates Coverage on YM BioSciences (YMI) with a Buy; Intriguing Opportunity
More News related to YMI
- YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
- YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
- YM BIOSCIENCES REPORTS CYT997 ORAL VASCULAR DISRUPTING AGENT RESULTS PRESENTED AT AACR-NCI-EORTC MEETING
- YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
- Merriman Curhan Ford Initiates Coverage on YM BioSciences (YMI) with a Buy; Intriguing Opportunity
Merriman Curhan Ford initiates coverage on YM BioSciences, Inc. (NYSE Amex: YMI) with a Buy. Valuation range $5.50-6.50.
Merriman analyst says, "We believe YM offers up an intriguing opportunity for investors including
growing revenue from nimotuzumab, a marketed product, significant market expansion potential for nimotuzumab and upside potential for pipeline products. After hitting previous hurdles on both the
data and perception fronts, YM has come a long way and we believe is poised to garner significant market share in the oncology market targeting EGFR due to nimotuzumab’s differentiated profile. We recommend that investors own YM BioSciences based on a definitive product opportunity and a compelling valuation."
To see more analyst ratings on YMI Click Here.
YM Biosciences Inc., a biopharmaceutical company, engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
